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 ABSTRACT 
OBJECTIVE: We seek to characterize the effect of progesterone metabolites on spontaneous 
and oxytocin-induced uterine contractility. 
STUDY DESIGN: Spontaneous contractility was studied in mouse uterine horns after treatment 
with  progesterone, 2α-hydroxyprogesterone, 6β-hydroxyprogesterone, 16α-hydroxyprogesterone 
or 17-hydroxyprogesterone caproate (17-OHPC) at 10-9 M to 10-6 M. Uterine horns were exposed 
to progestins (10-6 M), followed by increasing concentrations of oxytocin (1-100 nM) to study 
oxytocin-induced contractility. Contraction parameters were compared for each progestin and 
matched vehicle control using repeated-measures two-way ANOVA. In vitro metabolism of 
progesterone by recombinant CYP3A microsomes (3A5, 3A5, 3A7) identified major 
metabolites.  
RESULTS: Oxytocin-induced contractile frequency was decreased by 16α-hydroxyprogesterone 
(p=0.03) and increased by 6β-hydroxyprogesterone (p=0.05). Progesterone and 17-OHPC  
decreased oxytocin-induced contractile force (p=0.02, p=0.04, respectively) and frequency 
(p=0.02, p=0.03, respectively). Only progesterone decreased spontaneous contractile force 
(p=0.02). Production of 16α-hydroxyprogesterone and 6β-hydroxyprogesterone metabolites were 
confirmed in all CYP3A isoforms tested. 
CONCLUSION: Progesterone metabolites produced by maternal or fetal CYP3A enzymes 
influence uterine contractility. 
KEY WORDS: 16α-hydroxyprogesterone, 6β-hydroxyprogesterone, 17α -hydroxyprogesteone 
caproate, preterm labor, progesterone 
INTRODUCTION 
 Preterm birth affects 1 out of 9 neonates born in the United States, often resulting in 
increased infant morbidity and mortality.1 Infant mortality is most commonly caused by 
complications from extreme prematurity or low birth weight, particularly less than 28 weeks.2  A 
history of prior preterm birth and shortened cervical length have been identified as two risk 
factors for prematurity that can be targeted with pharmacotherapy.3 
 Progesterone and its analogues are the primary therapeutic options for prevention of 
preterm birth. Investigations of 17-hydroxyprogesterone caproate (17-OHPC) have demonstrated 
efficacy in the prevention of recurrent preterm birth in singleton pregnancies.4  Further, 
micronized progesterone has been proposed to decrease rates of preterm birth and neonatal 
morbidity in pregnant women with shortened cervical length.5 The mechanisms underlying the 
decreased rate of preterm birth are not well elucidated. Progesterone has been shown to decrease 
spontaneous contractions in myometrial tissue while increasing the threshold for stimulation.6  
Studies have also demonstrated decreased uterine contraction amplitude (force) after treatment 
with progesterone in an in vitro human myometrial model.7  However, clinical studies have been 
inconsistent, with some suggesting decreased contractility8 and others finding no improvement in 
rates of preterm labor.4  
 Metabolism of progesterone in the maternal-fetal dyad may produce molecules with 
biologic activity. The cytochrome P450 3A (CYP3A) family of enzymes is a major source of 
xenobiotic metabolism in both the mother and fetus. The ontogeny of CYP3A involves a change 
in expression from CYP3A7 during the fetal period to CYP3A4 and CYP3A5 after the first year 
of life. CYP3A7 is the dominant enzyme for metabolic oxidation of xenobiotics in the fetus, 
comprising 50% of the total cytochrome P450 content in the fetal liver.9 CYP3A metabolic 
activity has been characterized and is known to catalyze hydroxylation of the steroid ring 
structure at specific sites.10 Due to the prominence of CYP3A isoforms in both maternal and fetal 
livers, we hypothesize that it may play a role in the production of progesterone derivatives with 
biologic activity. In this study, we examine whether CYP3A metabolites of progesterone have 
non-genomic (acute) effects on spontaneous and oxytocin-induced uterine contractile force or 
frequency. 
  
MATERIALS AND METHODS 
2.1 Selection of Progestins 
 CYP3A has NADPH-dependent high catalytic activity at the 2-, 4-, 6β-, 16α-, and 16β-
positions on the steroid ring structure.10 Monohydroxylated derivatives of progesterone at these 
sites were considered potential products of CYP3A metabolism. Recombinant CYP3A4 
metabolism of progesterone has previously been demonstrated to produce 6β-
hydroxyprogesterone and 16α-hydroxyprogesterone.11 Three candidate metabolites were used in 
the experimental protocol: 4-pregnen-2α-ol-3,20-dione (2α-hydroxyprogesterone), 4-pregnen-6β-
ol-3,20-dione (6β-hydroxyprogesterone), and 4-pregnen-16α-ol-3,20-dione (16α-
hydroxyprogesterone).  Progesterone and 17-OHPC (4-pregnen-17-ol-3,20-dione caproate) were 
also selected for testing.  All progestins were obtained from a chemical supply vendor 
(Steraloids, Newport, RI).  
 All progestins were solubilized in ethanol and then diluted in PBS to the desired molar 
concentration.  Progesterone, 17-OHPC, and 6β-hydroxyprogesterone had an ethanol 
concentration of 0.001% at the 10-6 M dose (0.0001% at 10-7 M, 0.00001% at 10-8 M, 0.000001% 
at 10-9 M), while 2α-hydroxyprogesterone and 16α-hydroxyprogesterone had an ethanol 
concentration of 0.004% at the 10-6 M dose (0.0004% at 10-7 M, 0.00004% at 10-8 M, 0.000004% 
at 10-9 M). The concentration of ethanol decreased parallel the progestin dose in order to 
minimize the effect of the solvent on uterine contractility.  
2.2 Experimental Model 
 Approval for use of a murine model of uterine contractility was obtained through the 
Duke University Institutional Animal Care & Use Committee (IACUC). Virgin non-pregnant 
wild-type C57BL/6J female mice (Jackson Labs, Bar Harbor, ME) were obtained at 10-12 weeks 
of age and fed a standard diet.  Mice were euthanized by an IACUC-approved protocol and each 
of the two uterine horns were removed. A 1cm x 0.5cm segment of the uterine horn was 
suspended using 4-0 silk suture between a stainless steel wire hook connected to a Radnoti force 
displacement transducer (Radnoti LLC, Monrovia, CA) and a glass hook inside an organ bath 
that served as an anchor.  The bath was filled with modified Krebs buffer (118 mM NaCl, 4.8 M 
KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.5 mM CaCl2, 25 mM NaHCO3, and 11 mM glucose, 
pH 7.4), maintained at 37°C, and constantly bubbled with a premixed gas consisting of 20% O2, 
5% CO2, and balance N2.   Uterine horns equilibrated at 0.5 g of tension for approximately 30 
minutes until a spontaneous contraction pattern was established.  
 A total of 60 mice were utilized to assess the effect of the selected treatments on uterine 
contractility, 30 in the spontaneous contraction group and 30 in the oxytocin-induced group.  Six 
mice were in each progestin treatment group during both spontaneous and oxytocin-induced 
contractility arms of the study.  To determine the non-genomic (acute) effect of the progestin 
treatments on spontaneous uterine contractility, a segment of uterine horn from each mouse was 
exposed to a single progestin (progesterone, 17-OHPC, 2α-hydroxyprogesterone, 6β-
hydroxyprogesterone, or 16α-hydroxyprogesterone), while a segment of the contralateral horn 
was exposed to a matching dose of ethanol vehicle.   After a spontaneous contraction pattern was 
achieved, the progestin treatment was added to the tissue organ bath in successively increasing 
concentrations from 10-9 M to 10-6 M in 20-minute intervals. At the end of the treatments, the 
tissue was washed in modified Krebs buffer and then exposed to KCl (60mM) to elicit a tetanic 
response and confirm tissue viability.   
 To determine the non-genomic effect of progestin treatments on oxytocin-induced uterine 
contractility, we pretreated the uterine horns with a single progestin at 10-6 M for 10 minutes 
after a spontaneous contractile pattern was established. The contralateral horn from the same 
mouse was treated with ethanol vehicle at a matching concentration.  The uterine horns were 
subsequently exposed to increasing concentrations of oxytocin (1nM, 10nM, 50nM, and 100nM) 
in 10-minute intervals. At the end of the oxytocin treatments, the tissue was washed and then 
exposed to KCl (60mM) to elicit a tetanic response and confirm tissue viability. 
2.3 Statistical Analysis 
 Uterine contraction responses were recorded using LabChart Pro (ADInstruments, 
Colorado Springs, CO) software as the force generated with time (g*min).  Baseline uterine 
contractility was calculated as the area under the curve (AUC) for a ten-minute period of 
spontaneous contractions.  The AUC of the uterine contractile response to each treatment 
(progestin or oxytocin) was determined and expressed as a percentage of the baseline AUC 
observed during spontaneous contraction.  Spontaneous contractions in murine uterine muscle 
strips have previously been shown to have a linear correlation (r2 = 0.90) with the AUC 
following treatment with 1 nM oxytocin.12  To account for repeated measurements for individual 
muscle strips at increasing treatment doses, a repeated-measures two-way ANOVA model was 
used to compare the dose-response curves. Each dose-response curve was fit by nonlinear 
regression and compared using an Extra sum-of-squares F test. The mean max-fit response was 
compared between each progestin and vehicle control to determine maximum treatment efficacy. 
IC50 (spontaneous contractility) and EC50 (oxytocin-induced contractility) values were 
compared between each progestin and vehicle control to determine treatment potency. All 
analyses were performed using GraphPad Prism Version 6.0b for Macintosh (GraphPad 
Software, La Jolla, CA).  A p-value <0.05 was considered significant. 
2.4 Confirmation of Progesterone Metabolites 
CYP3A production of putative progestin metabolites was confirmed with in vitro metabolism 
studies. Baculovirus-inset cell - expressed human P450s (CYP3A4, CYP3A5, and CYP3A7) 
were purchased from Corning Inc. (Woburn, MA). All chemicals were of high performance 
liquid chromatography (HPLC) grade. Progesterone (100µM) was reconstituted with sodium 
phosphate buffer (100 mM, PH 7.4), MgSO4 (5mM), and recombinant human P450s (25 pmol). 
The reactions were initiated by adding NADPH (10mM), incubated for 30min, and terminated 
with an identical volume of ice-cold acetonitrile (ACN). The reaction mixtures were centrifuged 
(3000rpm x 5 minutes) and the supernatants were separated. An internal standard (6β-
hydroxytestosterone, 6β-OHT) and citric acid (0.1 M, PH 3.2) were added to each sample tube. 
Progesterone metabolites were extracted by mixing with 3ml of methyl tert-butyl ether (MTBE) 
and centrifugation (3000rpm x 5 minutes). The organic phase was removed and evaporated prior 
reconstitution in 100µl of mobile phase A, from which 70µl was injected onto the 
HPLC/uV/visible system described below. 
Serial dilutions of 16α-OHP and 6β-OHP were prepared (1mg/ml, methanol) for a standard 
curve. The total volume of the standards was the same as the incubation reaction volume in 
sodium phosphate buffer (100mM, PH 7.4). Extraction and separation of progestin standards was 
performed as described above. The 0ug/ml standard contained only the internal standard and the 
highest concentrations were based on the estimated metabolite formation. The quality controls 
(QC) were performed in triplicate along with standards.   
A profile of metabolites produced by progesterone was determined by HPLC/uV detection 
(254nm). An Agilent column Luna 5u C18 (2) 100A (250 X 4.6 mm) was used throughout the 
experiments. Samples and standards were run on a gradient (mobile phase B: 0min 40%; 1min 
40%; 28min 95%; 28.1min 40% and 30min 40%) with mobile phase A 0.25%/10%/90% (acetic 
acid/ACN/H2O) and mobile phase B 0.25%/90%/10% (acetic acid/ACN/H2O) at a flow rate 
1.0ml/min. Chromatographic peaks and retention times were confirmed by comparison with the 
standard curve. AUCs with corresponding retention times (6β-OHT: 5.74 min, 16α-OHP: 
8.74min, 6β-OHP: 11.44min) were collected.  
  
RESULTS 
 A representative tracing of an isolated uterine horn response to progesterone and vehicle 
control from the spontaneous uterine contractility experiment is shown in Figure 1A.  Horns 
treated with progesterone demonstrated a reduced spontaneous contractile force compared to 
vehicle control (43.9% vs. 64.1% of baseline AUC, p=0.02) at maximal treatment dose. No 
significant difference in spontaneous contractile force was seen at maximal treatment dose in 
horns treated with 17-OHPC (p=0.16), 2α-hydroxyprogesterone (p=0.78), 6β-
hydroxyprogesterone (p=0.53), or 16α-hydroxyprogesterone (p=0.27) compared with vehicle 
control.  A summary of spontaneous contractile force findings is provided in Table 1. 
 A representative tracing of an isolated uterine horn response to 16α-hydroxyprogesterone 
and vehicle control from the oxytocin-induced uterine contractility experiment is shown in 
Figure 1B.  Horns pre-treated with progesterone demonstrated a significant decrease in 
contractile force as measured by AUC at maximal oxytocin dose compared to vehicle control 
(266.8% vs. 497.5%, p=0.02). Uterine strips treated with 17-OHPC also demonstrated a 
significant decrease in contractile force compared to vehicle control (218.4% vs. 415.7%, 
p=0.04). There were no differences in oxytocin-induced contractile force at maximal dose (100 
nM) in horns pre-treated with 2α-hydroxyprogesterone (p=0.34), 6β-hydroxyprogesterone 
(p=0.91), or 16α-hydroxyprogesterone (p=0.07) compared to vehicle control. A summary of 
oxytocin-induced contractile force findings is provided in Table 1. 
 Spontaneous uterine contraction frequency was not significantly decreased after 
treatment with progesterone (p=0.99), 17-OHPC (p=0.68), 2α-hydroxyprogesterone (p=0.77), 
6β-hydroxyprogesterone (p=0.27), or 16α-hydroxyprogesterone (p=0.70) at maximal treatment 
dose compared to vehicle control.  However, oxytocin-induced contraction frequency decreased 
significantly after pre-treatment with progesterone (141% vs. 258% of baseline contraction 
frequency, p=0.02), 17-OHPC (130% vs. 219%, p=0.03), or 16α-hydroxyprogesterone (217% vs. 
365%, p=0.03), but not 2α-hydroxyprogesterone (p=0.12) compared to control (Figure 2).  6β-
hydroxyprogesterone demonstrated an increase in oxytocin-induced contraction frequency 
(196% vs. 152%, p=0.05) compared to control. Summaries of spontaneous contraction frequency 
findings and oxytocin-induced contraction frequency findings are provided in Table 1.  
The potency of each progestin treatment and matched vehicle control were compared 
through IC50 and EC50 values, as listed in Table 2. All progestin treatments had IC50 values <1 
nM in spontaneous contractile force dose-response curves and <1 nM to 10 nM in spontaneous 
contractile frequency curves. A greater range existed for EC50 values of progestin treatments in 
oxytocin-induced experiments. The EC50 values for oxytocin-induced contractile strength curves 
ranged from 5-150 nM, and from 3-650 nM for frequency curves. None of the IC50 or EC50 
values of progestin treatments significantly differed from matched vehicle controls in dose-
response curves.  
Endogenous production of the progesterone metabolites we tested was confirmed in vitro. 
The chromatographic profile of metabolites formed from incubation of progesterone with 
recombinant CYP3A4, CYP3A5, and CYP3A7 is shown in Figure 3. A peak for 16α-
hydroxyprogesterone appeared at approximately 8.6 minutes, consistent with commercial 
standards. Likewise, 6β-hydroxyprogesterone appeared at approximately 11.3 minutes. Both 
16α-hydroxyprogesterone and 6β-hydroxyprogesterone were identified as products of each 
CYP3A isoform tested. Overlap was seen between the peaks for 2α-hydroxyprogesterone and 
17α-hydroxyprogesterone at approximately 14 minute region. Progesterone was seen to elute at 
20.7 minutes.   
COMMENT 
 Progesterone and its esterified derivative 17-hydroxyprogesterone caproate are utilized 
clinically in women at risk for preterm delivery.  The pathway by which these progestins provide 
benefit is not known, but direct tocolytic effects may be partially responsible.  In this study, we 
explored three putative metabolites of progesterone, 2α-hydroxyprogesterone, 6β-
hydroxyprogesterone, and 16α-hydroxyprogesterone, for effects on uterine contractility in a 
murine model. None of the progesterone derivatives significantly diminished spontaneous 
contractile force. Spontaneous contractile frequency was not affected by the progesterone 
derivatives, though 16α-hydroxyprogesterone did significantly decrease oxytocin-induced 
contraction frequency. In contrast, treatment with 6β-hydroxyprogesterone led to a significant 
increase in oxytocin-induced contractile frequency but not force at maximal treatment dose. 
None of the progesterone metabolites demonstrated dose-response findings (IC50 or EC50) 
different from matched vehicle controls. Recombinant human microsome studies confirmed the 
production of 6β-hydroxyprogesterone and 16α-hydroxyprogesterone by both maternal and fetal 
CYP3A isoforms.  
 Although progesterone and 17-OHPC have closely related molecular structures, there are 
conflicting reports of their actions on myometrial tissue. Progesterone, but not 17-OHPC, has 
been shown to decrease contraction amplitude in ex vivo human myometrial strips.7 We included 
progesterone and 17-OHPC as treatment groups in this study as a comparison to the progesterone 
derivatives and to confirm earlier findings. Progesterone significantly decreased the force of 
spontaneous and oxytocin-induced contractions, while 17-OHPC only decreased the force of 
oxytocin-induced contractions. Spontaneous contraction frequency was not affected by 
progesterone or 17-OHPC, though both significantly decreased oxytocin-induced contraction 
frequency. However, the dose-response characteristics (IC50 or EC50) of progesterone and 17-
OHPC did not differ from matched vehicle controls. Despite these mixed results, progesterone 
and 17-OHPC have documented clinical efficacy in reduction of preterm birth4,5,8,13,14 and 
contraction frequency.8  
The discrepancy between dose-response characteristics (IC50 or EC50), which represent 
potency of the drugs tested, and maximum dose response, which represents efficacy of the drugs, 
is notable in our experiments. The ability of progesterone to inhibit uterine contractions has been 
well established. In our experiments, the maximal dose response of progesterone, but not the 
dose-response curve IC50 or EC50 value, differs from the vehicle control. Similarly, none of the 
progestins tested demonstrated potency different from the vehicle control, though several 
modulated efficacy at maximal dose. These findings suggest that the ethanol vehicle may be 
masking the potency, but not the efficacy, of the tested progestins. We feel that the maximal dose 
response of the progestins better reflects their ability to affect uterine contractility in our 
experimental model. 
 The search for alternate therapies to prevent preterm birth has included exploration of 
other progesterone derivatives. Modifications to the basic ring structure of progesterone can 
yield molecules with variable potency. The 5α/5β derivatives have been systematically compared 
to progesterone to determine which molecules have the greatest uterorelaxant effect in ex vivo rat 
myometrial strips. Reduction of bonds at the 3α,5α positions results in a 6-fold increased potency 
for uterorelaxant effect in comparison to progesterone. In comparison, reduction of bonds at the 
3β,5α positions results in <1/100th potency relative to progesterone.15 The uterorelaxant effect of 
the 5α/5β derivatives was observed in the micromolar concentration range,16 similar to the 
concentration required to see an effect in our experiments.  As our study focused on CYP3A 
metabolites of progesterone, we did not test the 5α/5β derivatives in this study. 
 CYP3A is a major metabolic enzyme family in the maternal and fetal livers. The 
progesterone metabolites tested were selected based on the oxidation pattern of CYP3A and a 
prior study of in vitro metabolism of CYP3A4.10,11 The recombinant CYP3A microsome 
experiments performed in the second part of our study confirmed the production of 6β-
hydroxyprogesterone and 16α-hydroxyprogesterone by CYP3A4, as well as the other CYP3A 
isoforms tested (CYP3A5, CYP3A7). Notably, 6β-hydroxyprogesterone and 16α-
hydroxyprogesterone demonstrated opposing effects on oxytocin-induced uterine contractility, 
suggesting that relative amounts of each progestin within the hormonal milieu of pregnancy may 
alter the likelihood of contractile activity. A recently published study on steroid metabolomics in 
the human fetus demonstrated 16α-hydroxyprogesterone in significantly lower concentrations in 
umbilical cord blood from preterm deliveries compared to term deliveries.17 Progesterone 
concentrations were found to be in the micromolar range, while concentrations of 16α-
hydroxyprogesterone were similar to 17α-hydroxyprogesterone in the nanomolar range. Our 
finding that these progesterone metabolites are produced by the maternal CYP3A homologs 
(CYP3A4/5) increases the biologic plausibility that they can reach myometrial tissues to 
modulate contractility.  
 Progestins may exert progestational effects via genomic or non-genomic pathways. This 
study was limited to investigation of immediate, non-genomic effects of the proposed 
metabolites due to the short treatment period. Progesterone has been shown to rapidly inhibit 
oxytocin-induced contractions in vitro by uncoupling the excitation-contraction process.18 
Furthermore, a metabolite of progesterone (5β-dihydroprogesterone) has been shown to act as a 
direct oxytocin receptor antagonist, further demonstrating the potential for non-genomic 
effects.19 Our study confirmed the rapid reduction of contractile force and frequency after 
progesterone treatment. Of the progesterone metabolites tested, 16α-hydroxyprogesterone 
demonstrated a rapid reduction in oxytocin-induced contraction frequency, while 6β-
hydroxyprogesterone increased oxytocin-induced contraction frequency. While our experiments 
did not explore the mechanism underlying this difference in action, it is likely that the position of 
mono-hydroxylation on the progesterone structure alters the chemical properties of the 
metabolites. It is possible that these structural changes may alter the binding affinity of the 
progesterone metabolites specifically for the oxytocin receptor or generally for a range of ion 
channels associated with smooth muscle contractility. We did not test oxytocin receptor binding 
of these metabolites in the current study, though future research efforts may investigate this as a 
potential mechanism for the observed effects on uterine contractility. 
 There are several limitations to our research: first, we utilized non-pregnant murine 
uterine horns in our experimentation. While we were able to discern novel effects of the 
progesterone metabolite treatments, use of pregnant myometrium would have better simulated 
the target environment at the time of labor. Changes to the transcriptome of human myometrium 
have been demonstrated at the time of spontaneous labor, signaling a specific environment 
different from non-laboring myometrium.20 Our use of wild-type mice to assess uterine 
contractility minimized any genetic variation that may have affected human myometrial 
contractility in our exploratory study. The variability in estrous phase of the mice at the time of 
contractility testing is a potential confounder. Each mouse served as its own control (one uterine 
horn treated with progestin, the contralateral horn treated with vehicle), which minimized the 
impact of estrous phase variations and allowed assessment of the impact of progestin treatment. 
While our use of uterine horns from non-pregnant mice is an accepted approach to the study of 
uterine contractility, progesterone metabolites should be tested in term human myometrium in 
future studies to confirm our findings in a pregnancy environment.  
Next, ethanol, which has inherent tocolytic activity, was used as a solvent for the lipophilic 
progestins. We controlled for this confounder by treating the contralateral uterine horn in each 
mouse with a matching concentration of ethanol to distinguish drug effect from vehicle effect. 
The uterine horns demonstrated an appropriate decrease in spontaneous contractility at the higher 
ethanol concentration of 0.004% (2α-OHP and 16α-OHP) compared to 0.001% (progesterone, 
17-OHPC, and 6β-OHP), though no effect was seen on oxytocin-induced contractility (Figure 4). 
However, dose-response curve characteristics (IC50 or EC50) of the progestin treatments were 
not distinguishable from the matched ethanol vehicles, limiting our ability to characterize the 
potency of the studied progestins. Uterine horns treated with ethanol vehicle also demonstrated 
greater variance in contractile response compared to progestin treatments. Future studies may be 
improved through the use of alternate lipophilic solvents (DMSO) or complexing with 
cyclodextrin to enhance aqueous solubility.   Additionally, progesterone is present in maternal 
plasma at higher concentrations than its metabolites (micromolar vs. nanomolar ranges, 
respectively), calling into question their potential importance. However, 17-hydroxyprogesterone 
is an example of a metabolite that has shown clinical efficacy from supplementation during 
pregnancy, suggesting that other progesterone metabolites may also have the potential for 
clinical effect. Finally, the large number of analyses performed makes it possible that some 
statistically significant findings may be due to chance. Repetition of these experiments in human 
myometrial tissue in pregnancy will be needed to confirm our findings. 
 Our results suggest that CYP3A-derived progesterone metabolites may be part of a 
progestin milieu that influences uterine contractility. An implication of this research is that 
individuals with CYP3A polymorphisms may have altered progestin profiles which may increase 
their propensity towards uterine contractility. Future studies may include confirmation of our 
findings in human pregnancy myometrial tissue, characterization of the progestin profile in term 
and preterm pregnancies, and investigation of genomic effects of the progesterone metabolites on 
uterine contractility. Continued investigation of progesterone metabolites may yield new insights 
into the physiologic mechanisms underlying variability in preterm labor.  
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TABLES 
Table 1. Spontaneous and oxytocin-induced contractility in response to progestin and vehicle treatments at maximal dose (10-6M). 
TREATMENT 
Contractile Force (% of baseline) Contractile Frequency/10 min (% of baseline) 
Drug Vehicle p value Drug Vehicle p value 
SPONTANEOUS    
Progesterone 44% 64% 0.02 48% 48% 0.99 
17-OHPCa 50% 40% 0.16 58% 55% 0.68 
2α-OHPb 38% 39% 0.78 54% 56% 0.77 
6β-OHPc 45% 50% 0.53 46% 56% 0.27 
16α-OHPd  37% 29% 0.27 57% 53% 0.70 
OXYTOCIN-INDUCED   
Legend: a17-OHPC, 17-hydroxyprogesterone caproate; b2α-OHP, 2α-hydroxyprogesterone; c6β-OHP, 6β-hydroxyprogesterone; d16α-
OHP, 16α-hydroxyprogesterone. P<0.05 is significant. 
 
Progesterone 267% 498% 0.02 141% 258% 0.02 
17-OHPCa 218% 416% 0.04 130% 219% 0.03 
2α-OHPb 330% 391% 0.34 169% 238% 0.12 
6β-OHPc 268% 263% 0.91 196% 152% 0.05 
16α-OHPd  302% 442% 0.07 217% 365% 0.03 
Table 2. Comparison of potency of progestin treatments and matched vehicle controls by IC50 and EC50 values in dose-response 
curves. 
TREATMENT Contractile Force Contractile Frequency 
SPONTANEOUS IC50 (nM) 95% CI p value IC50 (nM) 95% CI p value 
Progesterone 0.31 0.05 to 1.90 0.54 6.58 0.78 to 55.82 0.52 
vehicle 0.90 0.04 to 18.26  1.46 0.21 to 9.89  
17-OHPCa 0.78 0.15 to 3.92 0.96 0.31 0.01 to 8.77 0.68 
vehicle 0.28 0.03 to 2.29  0.55 0.04 to 7.86  
2α-OHPb 0.32 0.10 to 1.04 0.35 0.55 0.05 to 5.84 0.8 
vehicle 0.71 0.27 to 1.86  0.99 0.12 to 8.46  
6β-OHPc 0.48 0.08 to 2.97 0.59 4.10 0.65 to 25.80 0.68 
vehicle 0.32 0.04 to 2.79  6.76 0.99 to 46.40  
16α-OHPd 0.77 0.23 to 2.60 0.84 0.74 0.06 to 9.57 0.94 
vehicle 0.38 0.07 to 2.19  0.66 0.04 to 11.74  
OXYTOCIN-INDUCED EC50 (nM) 95% CI p value EC50 (nM) 95% CI p value 
progesterone 9.76 0.76 to 125.4 0.97 11.34 0.49 to 263.6 0.91 
vehicle 10.65 0.72 to 158.4  9.42 1.10 to 81.04  
17-OHPCa 8.43 2.9 to 24.52 0.89 3.26 0.18 to 58.09 0.72 
vehicle 10.80 1.22 to 96.00  5.73 1.03 to 32.05  
2α-OHPb 68.24 11.68 to 398.7 0.92 645.7 103.6 to 4024 0.74 
vehicle 32.88 4.99 to 216.8  4.29 0.18 to 102.0  
6β-OHPc 20.94 2.16 to 203.0 0.93 12.85 0.75 to 220.1 0.73 
vehicle 27.26 2.77 to 267.9  6.71 0.32 to 142.6  
16α-OHPd 142.50 28.13 to 721.7 0.99 8.46 0.83 to 86.46 0.89 
vehicle 11.65 0.49 to 277.2  10.81 1.11 to 105.7  
 
Legend: a17-OHPC, 17-hydroxyprogesterone caproate; b2α-OHP, 2α-hydroxyprogesterone; c6β-OHP, 6β-hydroxyprogesterone; d16α-
OHP, 16α-hydroxyprogesterone. P<0.05 is significant.
 
FIGURE LEGENDS 
Figure 1: Representative contraction tracings of uterine horns from wild-type (WT) C57BL/6J 
female mice. A: Uterine horns were isolated and suspended in a tissue organ bath at 0.5 g of 
tension. Once equilibrated, selected progestin treatments were added in successively increasing 
concentrations from 10-9 M to 10-6 M in 20-minute intervals to assess effect on spontaneous 
contractile activity (progesterone treatment, bottom panel). The contralateral horn from each 
mouse was treated with a matching ethanol vehicle (top panel). All contraction responses were 
measured and reported as the area under the contraction curve (AUC), normalized to the AUC of 
the spontaneous contraction pattern that preceded treatment. B: Treatment effect on oxytocin-
induced contractility was assessed by exposing horns to selected progestin treatments (10-6 M), 
followed by increasing doses of oxytocin (1, 10, 50, and 100 nM) in 10-minute intervals (bottom 
panel). The contralateral horn from each mouse was treated with a matching ethanol vehicle (top 
panel). Contraction responses were measured and reported as described above. 
Figure 2: Dose-response curves of oxytocin-induced uterine contractile frequency following 
progestin pre-treatment. Contraction frequency decreased significantly at maximal oxytocin dose 
(100 nM) after pre-treatment of uterine horns with progesterone (A, p=0.02), 17-OHPC (B, 
p=0.03), 6β-hydroxyprogesterone (D, p=0.05), or 16α-hydroxyprogesterone (E, p=0.03), but not 
2α-hydroxyprogesterone (C, p=0.12) compared to control. Error bars depict standard error (S.E). 
 
Figure 3: Chromatograms of metabolites formed from incubation of progesterone with CYP3A4 
(top panel), CYP3A5 (middle), and CYP3A7 (bottom). Peaks corresponding to 6β-
hydroxyprogesterone and 16α-hydroxyprogesterone are labeled.  
Figure 4: Dose-response curves of spontaneous and oxytocin-induced uterine contractile force 
for a composite of the vehicle controls. Nonlinear regression curves were fit to describe the 
spontaneous contraction dose response (top panel) seen from each vehicle treatment at 
successively increasing concentrations of 0.000001% to 0.001% (progesterone, 17-OHPC, and 
6β-OHP) and 0.000004% to 0.004% (2α-OHP and 16α-OHP). Dose-response curves of 
oxytocin-induced uterine contractions (bottom) after pretreatment with vehicle at maximal 
concentrations of 0.001% (progesterone, 17-OHPC, and 6β-OHP) and 0.004% (2α-OHP and 
16α-OHP).  
 

Figure 7. Oxytocin-Induced Contraction Frequency
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